Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Kawasaki disease recognition and treatment

Kimberly A. Morishita and Ran D. Goldman
Canadian Family Physician August 2020, 66 (8) 577-579;
Kimberly A. Morishita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

Question If a child presents to my office with several days of fever and a few features of Kawasaki disease (KD) but does not meet the diagnostic criteria, could they still have KD and is treatment needed?

Answer Presentations of KD have a range of clinical signs and symptoms. With the lack of a criterion standard test, the diagnosis of KD relies on syndrome recognition and a high index of suspicion in cases where KD does not present classically. It is still possible to have KD even if not all of the criteria are met, and these children are referred to as having incomplete forms of KD. The diagnosis of incomplete KD is usually made in a child or infant who presents with a history of prolonged fever, a few clinical criteria for KD, and other supportive features such as positive laboratory or echocardiographic findings. It is important to recognize children with incomplete forms of KD to avoid poor outcomes such as coronary artery aneurysms.

Kawasaki disease (KD) is a childhood vasculitis affecting the medium-sized muscular arteries, mainly the coronary arteries. It was first described in 1967 by the Japanese physician Dr Kawasaki as a mucocutaneous lymph node syndrome.1 The hallmark of KD is fever lasting 5 days or more, counting the day of fever onset as day 1, in addition to 4 or 5 of the principal clinical criteria (Box 1): cracking of lips or strawberry tongue, nonpurulent conjunctivitis, rash, erythema and edema of the hands and feet, and large unilateral cervical lymphadenopathy.

Box 1.

Criteria for the diagnosis of KD

Classic KD is diagnosed in the presence of fever for at least 5 days together with at least 4 of the 5 following principal clinical features.

  • Erythema and cracking of lips, strawberry tongue, or erythema of oral and pharyngeal mucosa

  • Bilateral bulbar conjunctival injection without exudate

  • Rash: maculopapular, diffuse erythroderma, or erythema multiforme–like

  • Erythema and edema of the hands and feet in the acute phase

  • Cervical lymphadenopathy (≥ 1.5 cm in diameter), usually unilateral

KD—Kawasaki disease.

Beyond syndrome recognition based on a combination of the clinical features, the diagnosis might be supported by positive laboratory or echocardiographic findings. While there are no specific diagnostic tests for KD, elevated erythrocyte sedimentation rate or C-reactive protein level, leukocytosis, and anemia are common. Thrombocytosis is frequently present, albeit usually in the second week of illness. Elevated serum transaminase, γ-glutamyl transpeptidase, bilirubin, and hypoalbuminemia levels, as well as sterile pyuria, are frequently described in the literature.

The pathogenesis of KD is unknown and is likely to be multifactorial, with epidemiologic information suggesting 1 or more infectious agents triggering KD in a genetically predisposed host. It is recognized that children of parents who have had KD have twice the risk of developing the disorder, and that having affected siblings increases the risk to 10-fold.2,3

Kawasaki disease presentation is very similar to other infections, particularly viral infections, which complicates the differential diagnosis. Furthermore, there are seasonal peaks in the winter and spring, and frequent descriptions of concurrent infections4–6—all pointing to a likely infectious element of KD.

Other than infections, the differential diagnosis of KD is broad and includes toxin-mediated syndromes (staphylococcal scalded skin syndrome and toxic shock syndrome); hypersensitivity reactions such as Stevens-Johnson syndrome, drug reactions, or acrodynia (pain and pink discoloration in the hands and feet most often seen in children chronically exposed to heavy metals, specifically mercury); and systemic-onset juvenile idiopathic arthritis.

Incomplete KD

In many cases, children will present to the physician’s office with fewer than 5 days of fever, or with fewer than 4 or 5 criteria but several findings compatible with KD. To avoid complications of KD (eg, coronary artery aneurysms)7–11 and to ensure early referral for treatment, the possibility of incomplete KD should be considered in these patients. Further laboratory or echocardiographic evaluation is warranted to determine the likelihood of incomplete KD and whether treatment is necessary. While in the past children with criteria below the threshold number were considered to have “atypical” KD, the American Heart Association and the American Academy of Pediatrics have recommended that the term incomplete KD be used, as these patients lack sufficient clinical signs to fulfil the classic criteria but do not demonstrate atypical features.12

It is estimated that 10% to 20% of children diagnosed with KD do not fulfil criteria for KD.13,14 Children with incomplete KD can present at any age15,16 but are more likely to be infants, who are at high risk of developing coronary artery aneurysms.17–20

Family physicians should consider the diagnosis of incomplete KD in any infant or child with prolonged unexplained fever, even if only a few principal features of KD are present.

Timely treatment

One of the prominent complications of KD is coronary artery aneurysms, documented in up to 25% of untreated patients.21 Timely treatment with intravenous immunoglobulin (IVIG) has been shown in clinical trials to reduce the risk of coronary artery aneurysms from 25% to 4%.22,23

Some children are at high risk of IVIG resistance,24 mostly those with young age (< 12 months), low albumin levels, thrombocytopenia, fever of less than 4 days, low sodium levels, or elevated transaminase levels.25–27

Acetylsalicylic acid is used in conjunction with IVIG, despite lack of clear evidence of any effect in prevention of coronary artery abnormalities.28 A moderate (30–50 mg/kg/d) to high dose (80–100 mg/kg/d) is provided until fever subsides, and a low dose (3–5 mg/kg/d) is prescribed for 6 to 8 weeks afterward (around the time the follow-up echocardiogram is performed).

The role of corticosteroids in the treatment of KD is a source of controversy and should be determined with a pediatrician experienced in the management of children with KD.15

Recovery

Most children with KD or incomplete KD will recover without any long-term sequelae, but up to 5% might have life-altering coronary artery aneurysms despite standard therapy. This has implications for long-term cardiac morbidity and requires anticoagulation therapy.22,23,29 Early referral to an emergency department, a pediatrician, or a rheumatologist is imperative for accurate diagnosis and judicious therapy.

Conclusion

The diagnosis of KD should be considered in any child with prolonged unexplained fever and any of the 5 principal clinical findings associated with the condition. However, early recognition and consideration of incomplete KD is essential for timely laboratory and echocardiographic evaluation and treatment of these patients who are at risk of delayed diagnosis and have higher rates of coronary artery aneurysms.

Notes

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Dr Morishita is a member and Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Kawasaki T
    . Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [article in Japanese]. Arerugi 1967;16(3):178-222.
    OpenUrlPubMed
  2. 2.↵
    1. Onouchi Y
    . Molecular genetics of Kawasaki disease. Pediatr Res 2009;65(5 Pt 2):46R-54R.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hata A,
    2. Onouchi Y
    . Susceptibility genes for Kawasaki disease: toward implementation of personalized medicine. J Hum Genet 2009;54(2):67-73. Epub 2009 Jan 16.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Son MBF,
    2. Newburger JW
    . Kawasaki disease. Pediatr Rev 2018;39(2):78-90.
    OpenUrlFREE Full Text
  5. 5.
    1. Benseler SM,
    2. McCrindle BW,
    3. Silverman ED,
    4. Tyrrell PN,
    5. Wong J,
    6. Yeung RSM
    . Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005;116(6):e760-6.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Turnier JL,
    2. Anderson MS,
    3. Heizer HR,
    4. Jone PN,
    5. Glodé MP,
    6. Dominguez SR
    . Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015;136(3):e609-14. Epub 2015 Aug 24.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Anderson MS,
    2. Todd JK,
    3. Glodé MP
    . Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics 2005;115(4):e428-33.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Minich LL,
    2. Sleeper LA,
    3. Atz AM,
    4. McCrindle BW,
    5. Lu M,
    6. Colan SD,
    7. et al
    . Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 2007;120(6):e1434-40. Epub 2007 Nov 19.
    OpenUrlAbstract/FREE Full Text
  9. 9.
    1. Wilder MS,
    2. Palinkas LA,
    3. Kao AS,
    4. Bastian JF,
    5. Turner CL,
    6. Burns JC
    . Delayed diagnosis by physicians contributes to the development of coronary artery aneurysms in children with Kawasaki syndrome. Pediatr Infect Dis J 2007;26(3):256-60.
    OpenUrlCrossRefPubMed
  10. 10.
    1. Witt MT,
    2. Minich LL,
    3. Bohnsack JF,
    4. Young PC
    . Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999;104(1):e10.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Koren G,
    2. Lavi S,
    3. Rose V,
    4. Rowe R
    . Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108(3):388-92.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Newburger JW,
    2. Takahashi M,
    3. Gerber MA,
    4. Gewitz MH,
    5. Tani LY,
    6. Burns JC,
    7. et al
    . Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110(17):2747-71.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Fukushige J,
    2. Takahashi N,
    3. Ueda Y,
    4. Ueda K
    . Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994;83(10):1057-60.
    OpenUrlPubMed
  14. 14.↵
    1. Nakamura Y,
    2. Yashiro M,
    3. Uehara R,
    4. Sadakane A,
    5. Chihara I,
    6. Aoyama Y,
    7. et al
    . Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J Epidemiol 2010;20(4):302-7. Epub 2010 Jun 5.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. McCrindle BW,
    2. Rowley AH,
    3. Newburger JW,
    4. Burns JC,
    5. Bolger AF,
    6. Gewitz M,
    7. et al
    . Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017;135(17):e927-99. Erratum in: Circulation 2019;140(5):e181–4. Epub 2019 Jul 29.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Manlhiot C,
    2. Christie E,
    3. McCrindle BW,
    4. Rosenberg H,
    5. Chahal N,
    6. Yeung RSM
    . Complete and incomplete Kawasaki disease: two sides of the same coin. Eur J Pediatr 2012;171(4):657-62. Epub 2011 Dec 3.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Yeom JS,
    2. Woo HO,
    3. Park JS,
    4. Park ES,
    5. Seo JH,
    6. Youn HS
    . Kawasaki disease in infants. Korean J Pediatr 2013;56(9):377-82. Epub 2013 Sep 30.
    OpenUrlCrossRefPubMed
  18. 18.
    1. Yanagawa H,
    2. Tuohong Z,
    3. Oki I,
    4. Nakamura Y,
    5. Yashiro M,
    6. Ojima T,
    7. et al
    . Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease. Pediatr Cardiol 1999;20(4):248-51.
    OpenUrlCrossRefPubMed
  19. 19.
    1. Burns JC,
    2. Wiggins JW Jr,
    3. Toews WH,
    4. Newburger JW,
    5. Leung DY,
    6. Wilson H,
    7. et al
    . Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986;109(5):759-63.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Chang FY,
    2. Hwang B,
    3. Chen SJ,
    4. Lee PC,
    5. Meng CCL,
    6. Lu JH
    . Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006;25(3):241-4.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Kato H,
    2. Sugimura T,
    3. Akagi T,
    4. Sato N,
    5. Hashino K,
    6. Maeno Y,
    7. et al
    . Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94(6):1379-85.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Newburger JW,
    2. Takahashi M,
    3. Burns JC,
    4. Beiser AS,
    5. Chung KJ,
    6. Duffy CE,
    7. et al
    . The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315(6):341-7.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Terai M,
    2. Shulman ST
    . Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131(6):888-93.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Aydin EA,
    2. Ertugrul I,
    3. Bilginer Y,
    4. Batu ED,
    5. Sonmez HE,
    6. Demir S,
    7. et al
    . The factors affecting the disease course in Kawasaki disease. Rheumatol Int 2019;39(8):1343-9. Epub 2019 May 28.
    OpenUrl
  25. 25.↵
    1. Kobayashi T,
    2. Inoue Y,
    3. Takeuchi K,
    4. Okada Y,
    5. Tamura K,
    6. Tomomasa T,
    7. et al
    . Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113(22):2606-12. Epub 2006 May 30.
    OpenUrlAbstract/FREE Full Text
  26. 26.
    1. Egami K,
    2. Muta H,
    3. Ishii M,
    4. Suda K,
    5. Sugahara Y,
    6. Iemura M,
    7. et al
    . Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149(2):237-40.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Sano T,
    2. Kurotobi S,
    3. Matsuzaki K,
    4. Yamamoto T,
    5. Maki I,
    6. Miki K,
    7. et al
    . Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166(2):131-7. Epub 2006 Aug 1.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Baumer JH,
    2. Love SJL,
    3. Gupta A,
    4. Haines LC,
    5. Maconochie I,
    6. Dua JS
    . Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006;(4):CD004175.
  29. 29.↵
    1. Michihata N,
    2. Matsui H,
    3. Fushimi K,
    4. Yasunaga H
    . Guideline-concordant treatment of Kawasaki disease with immunoglobulin and aspirin and the incidence of coronary artery aneurysm. Clin Pediatr (Phila) 2015;54(11):1076-80. Epub 2015 Jan 8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (8)
Canadian Family Physician
Vol. 66, Issue 8
1 Aug 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Kawasaki disease recognition and treatment
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Kawasaki disease recognition and treatment
Kimberly A. Morishita, Ran D. Goldman
Canadian Family Physician Aug 2020, 66 (8) 577-579;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Kawasaki disease recognition and treatment
Kimberly A. Morishita, Ran D. Goldman
Canadian Family Physician Aug 2020, 66 (8) 577-579;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Incomplete KD
    • Timely treatment
    • Recovery
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
Show more Practice

Child Health Update

  • Anterior cutaneous nerve entrapment syndrome in children
  • Neuroimaging to diagnose central nervous system tumours in children
  • Corticosteroids for infectious mononucleosis
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire